Bajaj Healthcare LimitedBAJAJHCARECorporate

Pharmaceuticals - Indian - Bulk Drugs & Formln Latest results: Sep 2025 4 quarters of data

₹341.10

MCap ₹1,148 Cr

Bajaj Healthcare Limited — Stock analysis & AI research Bajaj Healthcare Limited — Multibagger AI analysis Bajaj Healthcare Limited — Seasonality — best & worst months Bajaj Healthcare Limited — Technical setup — score, trend, support & resistance Bajaj Healthcare Limited — Live exchange announcements

📈 MACD Bullish Crossover 📈 Stocks Above Anchored VWAP 🏭 Pharma sector

AI-assisted data: figures and text on this page are extracted from public quarterly filings with AI assistance, checked automatically and overseen by our editorial team (human in the loop). They may still contain errors or omissions. Verify critical numbers against official company / SEBI / NSE / BSE filings before making any decision. Educational information only, not financial advice.

₹148 Cr

Sales · Sep 2025

₹27 Cr

Operating Profit · Sep 2025

18.2%

OPM % · Sep 2025

₹11 Cr

Net Profit · Sep 2025

₹3.53

EPS · Sep 2025

📝 Bajaj Healthcare Limited — results explained

Quarter ended September 2025 (Q2 FY26)

Bajaj Healthcare Limited reported revenue of ₹148 crore for the quarter ended September 2025 (Q2 FY26), and down 0.6% sequentially over the June 2025 quarter.

Net profit stood at ₹11 crore. Earnings per share (EPS) came in at ₹3.53.

Operating profit stood at ₹27 crore — an operating margin (OPM) of 18.2%.

Valuation snapshot

At the current price of ₹341.10, BAJAJHCARE has a market capitalisation of ₹1,148 crore.

Within the Pharmaceuticals - Indian - Bulk Drugs & Formln industry, it is the 25th-largest of the 47 companies we track by market value.

Shareholding pattern

As of Mar 2026, promoters held 58.29%, foreign institutional investors (FIIs) 1.98%, domestic institutional investors (DIIs) 2.91%, public shareholders 36.82% of Bajaj Healthcare Limited.

Promoter holding slipped from 59.19% to 58.29% over the latest period.

📈 Share price & events

📊 Quarterly trend

₹ crore · OPM % on right axis

🎯 Key metrics

price-linked ratios use the latest close

Valuation

Market Cap ?

₹1,148 Cr

Current Price ?

₹341.1

P/E ?

N/A

Industry P/E ?

37.20

P/B ?

2.15

P/S ?

N/A

P/FCF ?

63.80

Enterprise Value ?

₹1,397 Cr

EV/EBITDA ?

N/A

PEG ?

N/A

Earnings Yield ?

N/A

Dividend Yield ?

N/A

Profitability & Returns

Sales (TTM) ?

N/A

OPM ?

N/A

Profit after tax (TTM) ?

N/A

EPS (TTM) ?

N/A

ROCE ?

11.0%

ROE ?

N/A

ROA ?

N/A

Growth

Sales — latest qtr ?

₹148 Cr

PAT — latest qtr ?

₹11 Cr

YoY qtr sales growth ?

N/A

YoY qtr profit growth ?

N/A

Sales growth (3y) ?

N/A

Sales growth (5y) ?

N/A

Profit growth (3y) ?

N/A

Profit growth (5y) ?

N/A

Financial Health

Debt ?

₹249 Cr

Debt to Equity ?

0.47

Interest Coverage ?

N/A

Current Ratio ?

N/A

Ownership

Promoter holding ?

58.29%

Change in promoter holding ?

-0.90%

Pledged percentage ?

N/A

Market

Return 3 months ?

-8.8%

Return 6 months ?

-2.4%

🗓️ Quarterly results (4 quarters · ₹ Cr)

same fiscal quarter as Sep bestweakest per row · for costs (interest, NPAs) low is best Highlight

Metric	Dec 2023	Dec 2024	Jun 2025	Sep 2025	YoY %	QoQ %
Sales	109	123	149	148	—	-0.6%
Operating Profit	20	22	25	27	—	+10.0%
Other Income	1	2	1	2	—	+88.3%
Interest	7	6	5	6	—	+6.4%
Depreciation	7	7	6	7	—	+25.6%
Profit Before Tax	6	12	14	16	—	+13.4%
Net Profit	-2	12	12	11	—	-6.1%
EPS	-0.80	3.65	3.74	3.53	—	-5.6%
OPM %	18.0%	17.6%	16.5%	18.2%	—	+10.3%

📆 Annual results (₹ Cr, FY = Apr–Mar)

Annual rollup not yet available We need at least 3 quarters of a fiscal year to compute annual figures. This symbol does not yet have a complete fiscal year in our database.

🏛️ Balance Sheet (latest 4 periods)

Metric	Mar 2023	Mar 2024	Mar 2025	Mar 2026	% Chg
Equity Capital	14	14	16	17	+6.2%
Reserves	354	265	450	516	+14.7%
Borrowings	415	333	223	249	+11.7%
Other Liabilities	115	154	144	141	-2.1%
Total Liabilities	898	765	833	923	+10.8%
Fixed Assets	366	253	238	248	+4.2%
CWIP	22	7	3	8	+166.7%
Investments	0	0	0	0	—
Other Assets	510	506	591	667	+12.9%
Total Assets	898	765	833	923	+10.8%

💧 Cash Flow (latest 4 periods)

Metric	Mar 2023	Mar 2024	Mar 2025	Mar 2026	% Chg
Cash from Operating Activity	-22	92	22	58	+163.6%
Cash from Investing Activity	-93	-11	-15	-48	-220.0%
Cash from Financing Activity	131	-97	-6	24	+500.0%
Net Cash Flow	16	-16	0	35	—
Free Cash Flow	-115	73	10	18	+80.0%
CFO/OP	-10%	138%	32%	53%	+65.6%

➗ Ratios (latest 4 periods)

Metric	Mar 2023	Mar 2024	Mar 2025	Mar 2026	% Chg
Debtor Days	110	139	169	140	-17.2%
Inventory Days	199	206	206	249	+20.9%
Days Payable	81	128	122	133	+9.0%
Cash Conversion Cycle	228	217	254	256	+0.8%
Working Capital Days	27	-0	140	119	-15.0%
ROCE %	14%	8%	11%	11%	+0.0%

👥 Shareholding (latest 4 periods)

Metric	Jun 2025	Sep 2025	Dec 2025	Mar 2026	% Chg
Promoters	59.19%	59.19%	59.19%	58.29%	-1.5%
FIIs	1.09%	1.12%	1.18%	1.98%	+67.8%
DIIs	3.16%	2.99%	2.96%	2.91%	-1.7%
Public	36.56%	36.70%	36.67%	36.82%	+0.4%
No. of Shareholders	35,980	38,576	37,953	38,158	+0.5%

⚖️ Peer comparison

Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln · top 25 of 47 companies · full page →

#	Company	CMP	MCap (Cr)	P/E	Sales TTM	NP TTM	OPM%	NPM%	Sales YoY%	NP YoY%	Qtr Rev Δ%	Qtr NP Δ%
1	AKUMS Akums Drugs	₹784.55	12,012	41.2	4,502	293	12.6%	6.5%	5.9%	-25.5%	13.9%	56.1%
2	STAR Strides Pharma	₹1,085.00	10,001	26.7	3,636	389	25.4%	10.7%	-20.4%	99.0%	11.2%	50.0%
3	BLUEJET Blue Jet	₹565.05	9,802	36.9	884	265	36.3%	30.0%	8.0%	0.7%	-17.5%	-14.3%
4	AARTIPHARM Aarti Pharmalabs	₹828.30	7,511	36.1	1,957	208	22.0%	10.6%	1.5%	-26.9%	42.4%	39.2%
5	SUPRIYA Supriya Lifescience	₹870.30	7,004	35.3	873	198	33.2%	22.7%	18.9%	11.1%	30.8%	-30.9%
6	INNOVACAP Innova Captab	₹1,199.30	6,863	13.8	5,779	497	14.6%	8.6%	355.1%	277.4%	33.9%	42.3%
7	MOREPENLAB Morepen Laboratories	₹123.35	6,759	48.0	1,951	141	9.4%	7.2%	-0.3%	-18.3%	34.1%	394.0%
8	IOLCP IOL Chemicals	₹201.19	5,905	35.2	2,523	168	12.3%	6.7%	11.5%	36.6%	37.1%	89.8%
9	FDC FDC	₹350.20	5,702	19.5	2,191	291	15.3%	13.3%	3.0%	4.8%	3.0%	9.5%
10	NOVARTIND Novartis India	₹2,257.80	5,575	57.0	371	97	27.6%	26.2%	-0.3%	-6.9%	18.2%	14.3%
11	ORCHPHARMA Orchid Pharma	₹1,058.75	5,370	236.9	812	22	5.1%	2.7%	-11.9%	-76.4%	0.2%	25.4%
12	RPGLIFE RPG Life	₹2,865.90	4,740	39.7	735	120	21.1%	16.3%	8.4%	-36.9%	15.8%	16.3%
13	ZOTA Zota Health	₹1,232.70	4,269	—	609	-104	0.6%	-17.1%	84.6%	-29.8%	66.9%	-213.9%
14	GUFICBIO Gufic Biosciences	₹419.85	4,210	57.3	974	74	16.9%	7.6%	14.7%	-9.1%	14.9%	86.0%
15	UNICHEMLAB Unichem Laboratories	₹526.70	3,708	12.2	2,308	305	9.9%	13.2%	6.2%	74.1%	20.1%	496.1%
16	INDSWFTLAB Ind-Swift Laboratories	₹374.00	3,252	55.4	665	57	9.0%	8.6%	235.3%	10.1%	32.3%	-88.7%
17	ADVENZYMES Advanced Enzyme	₹293.25	3,249	19.8	750	172	29.8%	22.9%	17.1%	29.6%	2.1%	-4.6%
18	SOLARA Solara Active	₹667.00	3,218	85.6	1,535	37	15.2%	2.4%	6.6%	-1470.4%	33.1%	381.8%
19	DCAL Dishman Carbogen	₹162.08	2,541	157.6	2,902	16	16.7%	0.6%	8.1%	2655.7%	-4.3%	-351.7%
20	INDOCO Indoco Remedies	₹254.59	2,347	n/m	1,872	3	8.8%	0.2%	10.7%	-26.5%	6.5%	280.0%
21	PANACEABIO Panacea Biotec	₹368.55	2,257	—	673	-9	0.3%	-1.3%	14.4%	17.9%	19.7%	-44.4%
22	REMUS Remus Pharma.	₹1,911.30	2,252	91.1	94	25	31.7%	26.7%	—	—	13.3%	21.4%
23	SAKAR Sakar Healthcare	₹987.40	2,167	61.0	272	36	28.5%	13.3%	41.9%	71.8%	38.4%	120.2%
24	JAGSNPHARM Jagsonpal Pharmaceuticals	₹227.53	1,501	33.3	294	45	20.7%	15.4%	6.9%	-22.2%	8.5%	20.4%
25	BAJAJHCARE Bajaj Healthcare	₹327.00	1,101	60.7	628	18	17.5%	2.9%	12.7%	-59.1%	11.4%	16.7%

❓ Frequently asked questions

What was Bajaj Healthcare Limited's revenue in Q2 FY26?